Melbourne presentation was also excellent. Wolfgang confirmed that Italian distributor now applying for reimbursements and that now they have the double blind clinical trials should have sufficient evidence. Slight possibility in Germany they might need economic figures to back up how the device can also save the health system $$. But this should be very simple. The figures we have for Australian estimate $40-60K per annum as the treatment cost for an autistic child. Compare that with $3k once off for home-based Mente device.
Also in US i was surprised to learn that reimbursements can be used differently so that the class of "neurofeedback" can qualify for reimbursement. So if we get FDA on the Mente, the rollout in to the US could be super fast as users may be able to get the Mente at minimal personal cost.
With the margin on this device, the moment we start seeing traction on sales occurring, i think the market is really going to wake up to the opportunity.
NTI Price at posting:
16.0¢ Sentiment: Hold Disclosure: Held
